Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Fiera Capital Corp

Fiera Capital Corp cut its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 3.0% in the third quarter, HoldingsChannel reports. The institutional investor owned 466,075 shares of the company’s stock after selling 14,334 shares during the quarter. Fiera Capital Corp’s holdings in Crinetics Pharmaceuticals were worth $23,816,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Driehaus Capital Management LLC grew its holdings in Crinetics Pharmaceuticals by 17.0% in the second quarter. Driehaus Capital Management LLC now owns 6,112,173 shares of the company’s stock valued at $273,764,000 after purchasing an additional 885,876 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Crinetics Pharmaceuticals by 27.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,823,218 shares of the company’s stock valued at $178,966,000 after buying an additional 814,360 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Crinetics Pharmaceuticals by 2.1% in the first quarter. Vanguard Group Inc. now owns 3,575,076 shares of the company’s stock worth $167,349,000 after acquiring an additional 72,624 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Crinetics Pharmaceuticals by 264.1% in the first quarter. Janus Henderson Group PLC now owns 1,978,172 shares of the company’s stock valued at $92,526,000 after acquiring an additional 1,434,909 shares in the last quarter. Finally, Artal Group S.A. acquired a new stake in shares of Crinetics Pharmaceuticals during the first quarter valued at $65,088,000. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Insider Transactions at Crinetics Pharmaceuticals

In related news, insider Dana Pizzuti sold 14,375 shares of the firm’s stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $54.63, for a total transaction of $785,306.25. Following the completion of the sale, the insider now directly owns 28,507 shares of the company’s stock, valued at approximately $1,557,337.41. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Dana Pizzuti sold 14,375 shares of the business’s stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $54.63, for a total value of $785,306.25. Following the completion of the sale, the insider now owns 28,507 shares of the company’s stock, valued at approximately $1,557,337.41. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Marc Wilson sold 25,000 shares of Crinetics Pharmaceuticals stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $51.11, for a total value of $1,277,750.00. Following the completion of the transaction, the chief financial officer now owns 111,092 shares of the company’s stock, valued at $5,677,912.12. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,410 shares of company stock valued at $2,275,929. Corporate insiders own 6.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CRNX shares. Cantor Fitzgerald restated an “overweight” rating and issued a $90.00 target price on shares of Crinetics Pharmaceuticals in a report on Monday, September 16th. Oppenheimer restated an “outperform” rating and set a $73.00 target price (down previously from $74.00) on shares of Crinetics Pharmaceuticals in a research report on Friday, August 9th. HC Wainwright boosted their price target on Crinetics Pharmaceuticals from $60.00 to $69.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, JMP Securities restated a “market outperform” rating and set a $80.00 price objective on shares of Crinetics Pharmaceuticals in a report on Friday, September 27th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $68.55.

Crinetics Pharmaceuticals Stock Up 1.5 %

Shares of CRNX stock opened at $60.69 on Friday. Crinetics Pharmaceuticals, Inc. has a fifty-two week low of $25.75 and a fifty-two week high of $60.93. The firm’s 50 day moving average price is $54.31 and its two-hundred day moving average price is $50.70. The stock has a market cap of $4.86 billion, a price-to-earnings ratio of -16.06 and a beta of 0.62.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.08). The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.47 million. The business’s quarterly revenue was down 59.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.94) earnings per share. On average, equities analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.